These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27672337)

  • 21. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
    Calzetta L; Di Marco F; Blasi F; Cazzola M; Centanni S; Micheletto C; Rossi A; Rogliani P
    Pulm Pharmacol Ther; 2019 Dec; 59():101855. PubMed ID: 31639476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aclidinium bromide combined with formoterol inhibits remodeling parameters in lung epithelial cells through cAMP.
    Lambers C; Costa L; Ying Q; Zhong J; Lardinois D; Dekan G; Schuller E; Roth M
    Pharmacol Res; 2015 Dec; 102():310-8. PubMed ID: 26546746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
    Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
    Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany.
    Rivero-Ferrer E; Olesen M; Plana E; Aguado J; Saigí-Morgui N; Rubino A; Daoud SZ; Lei A; Perez-Gutthann S; Schink T; Kristiansen NS; Hallas J; Pottegård A; Rebordosa C
    Clin Drug Investig; 2022 Apr; 42(4):319-331. PubMed ID: 35290649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.
    D'Urzo T; Donohue JF; Price D; Miravitlles M; Kerwin E
    Expert Rev Respir Med; 2015 Oct; 9(5):519-32. PubMed ID: 26366803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How the cost-effectiveness results change in the China health policy environment: an economic evaluation of glycopyrrolate/formoterol for the treatment of COPD.
    Wang L; Gu W; Zhang X; Fu S; Zhang D; Guan X; Li H; Ma A
    J Med Econ; 2022; 25(1):356-366. PubMed ID: 35184671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
    Babu KS; Morjaria JB
    Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New combinations in the treatment of COPD: rationale for aclidinium-formoterol.
    Incorvaia C; Montagni M; Makri E; Ridolo E
    Ther Clin Risk Manag; 2016; 12():209-15. PubMed ID: 26929634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China.
    Lan Y; Yang N; Wang Y; Yang Y; Xu M; He Q
    Int J Chron Obstruct Pulmon Dis; 2023; 18():2093-2103. PubMed ID: 37767047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date.
    Moitra S; Bhome AB; Brashier BB
    Drug Des Devel Ther; 2015; 9():1989-99. PubMed ID: 25897208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease.
    Zhang H; Daoud SZ; Gillen MS; Calderon N; Heijer M; Molins E; Garcia-Gil E; Chen H; Li Q; Liu C; Ding Y
    Drugs R D; 2022 Mar; 22(1):35-42. PubMed ID: 35133636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
    Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Real-World Study on the Day and Night-Time Symptoms Among Greek COPD Patients Who Recently Initiated Treatment with Dual Bronchodilation: The DANICO Study.
    Kostikas K; Dimakou K; Gourgoulianis K; Gaga M; Papapetrou D; Tsoukalas G; Chatziapostolou P; Antoniadis A; Meletis G; Evangelopoulou E; Styliara P; Karypidou I; Gogali A; Kalafatakis K; Tzanakis N
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2027-2041. PubMed ID: 36072610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Formoterol: a review of its use in chronic obstructive pulmonary disease.
    Cheer SM; Scott LJ
    Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
    Maltais F; Milot J
    Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M; Briggs AH; Grossman RF; Rance L
    Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study.
    Fuhr R; Leselbaum A; Aubets J
    Clin Pharmacol Drug Dev; 2016 Mar; 5(2):109-17. PubMed ID: 27138024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
    Blasi F; Canonica GW; Miravitlles M
    Respir Res; 2017 Jan; 18(1):19. PubMed ID: 28100244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
    Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
    Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.